Selected Publications

Academic Article

Year Title Altmetric
2022 Corrigendum to: Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform (Human Mutation, (2020), 41, 6, (1131-1137), 10.1002/humu.24008)Human Mutation.  43:1344. 2022
2021 Regulation of GFAP ExpressionASN Neuro.  13. 2021
2020 Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoformHuman Mutation.  41:1131-1137. 2020
2020 GFAP at 50ASN Neuro.  12. 2020
2019 Relative stabilities of wild-type and mutant glial fibrillary acidic protein in patients with Alexander diseaseJournal of Biological Chemistry.  294:15604-15612. 2019
2019 AP-1 and the injury response of the GFAP geneJournal of Neuroscience Research.  97:149-161. 2019
2016 Composition of Rosenthal Fibers, the Protein Aggregate Hallmark of Alexander DiseaseJournal of Proteome Research.  15:2265-2282. 2016
2015 Elevated GFAP induces astrocyte dysfunction in caudal brain regions: A potential mechanism for hindbrain involved symptoms in type II Alexander diseaseGlia.  63:2285-2297. 2015
2015 A new mutation in GFAP widens the spectrum of Alexander diseaseEuropean Journal of Human Genetics.  23:1-2. 2015
2014 Changes in the morphology and proliferation of astrocytes induced by two modalities of chemically functionalized single-walled carbon nanotubes are differentially mediated by glial fibrillary acidic protein 2014
2014 Role of GFAP in CNS injuriesNeuroscience Letters.  565:7-13. 2014
2013 Transgenic analysis of GFAP promoter elementsGlia.  61:1488-1499. 2013
2012 Splice site, frameshift, and chimeric GFAP mutations in Alexander diseaseHuman Mutation.  33:1141-1148. 2012
2012 Alexander disease 2012
2012 Archetypal and new families with Alexander disease and novel mutations in GFAPJAMA Neurology.  69:208-214. 2012
2011 GFAP mutations, age at onset, and clinical subtypes in Alexander diseaseNeurology.  77:1287-1294. 2011
2010 Alteration Of glial-neuronal metabolic interactions in a mouse model of Alexander diseaseGlia.  58:1228-1234. 2010
2010 Drug screening to identify suppressors of GFAP expressionHuman Molecular Genetics.  19:3169-3178. 2010
2009 An infantile case of Alexander disease unusual for its MRI features and a GFAP allele carrying both the p.Arg79His mutation and the p.Glu223Gln coding variantJournal of Neurology.  256:679-682. 2009
2008 Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brainJournal of Gene Medicine.  10:583-592. 2008
2008 GFAP promoter elements required for region-specific and astrocyte-specific expressionGlia.  56:481-493. 2008
2008 Adult-onset Alexander disease with progressive ataxia and palatal tremorMovement Disorders.  23:118-122. 2008
2007 GFAP and its role in Alexander diseaseExperimental Cell Research.  313:2077-2087. 2007
2006 Enhanced hippocampal neurodegeneration after traumatic or kainate excitotoxicity in GFAP-null miceJournal of Clinical Neuroscience.  13:934-938. 2006
2006 Astrocyte heterogeneity revealed by expression of a GFAP-LacZ transgeneGlia.  53:677-687. 2006
2006 Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elementsJournal of Neuroscience Research.  83:744-753. 2006
2006 Propensity for paternal inheritance of de novo mutations in Alexander diseaseHuman Genetics.  119:137-144. 2006
2006 The Alexander disease-causing glial fibrillary acidic protein mutant, R416W, accumulates into Rosenthal fibers by a pathway that involves filament aggregation and the association of αB-crystallin and HSP27American Journal of Human Genetics.  79:197-213. 2006
2005 Erratum: Unusual variants of Alexander's disease (Annals of Neurology (2005) 57 (327-338))Annals of Neurology.  58:172. 2005
2005 Alexander-disease mutation of GFAP causes filament disorganization and decreased solubility of GFAPJournal of Cell Science.  118:2057-2065. 2005
2005 Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander diseaseAnnals of Neurology.  57:310-326. 2005
2005 Unusual variants of Alexander's diseaseAnnals of Neurology.  57:327-338. 2005
2004 Expression specificity of GFAP transgenesNeurochemical Research.  29:2075-2093. 2004
2004 Expression specificity of GFAP transgenes.Neurochemical Research.  29:2075-2093. 2004
2004 Dominantly-inherited adult-onset leukodystrophy with palatal tremor caused by a mutation in the glial fibrillary acidic protein geneMovement Disorders.  19:1244-1248. 2004
2004 Expression of glial fibrillary acidic protein in primary cultures of human Müller cellsExperimental Eye Research.  79:423-429. 2004
2003 Alexander's disease: Clinical, pathologic, and genetic featuresJournal of Child Neurology.  18:625-632. 2003
2003 GFAP: Functional implications gleaned from studies of genetically engineered miceGlia.  43:87-90. 2003
2003 Alexander disease: GFAP mutations unify young and oldLancet Neurology.  2:75. 2003
2002 GFAP mutations in Alexander diseaseInternational Journal of Developmental Neuroscience.  20:259-268. 2002
2002 Molecular findings in symptomatic and pre-symptomatic Alexander disease patientsNeurology.  58:1494-1500. 2002
2002 ICP monitoring following bilateral carotid occlusion in GFAP-null mice 2002
2001 hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo 2001
2001 A novel mutation in glial fibrillary acidic protein gene in a patient with Alexander diseaseNeuroscience Letters.  312:71-74. 2001
2001 Differential cellular expression of tumor necrosis factor-α and Type I tumor necrosis factor receptor after transient global forebrain ischemiaJournal of the Neurological Sciences.  186:87-99. 2001
2001 Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander diseaseNature Genetics.  27:117-120. 2001
2001 Alexander disease: New insights from geneticsJournal of Neuropathology and Experimental Neurology.  60:563-573. 2001
2001 Infantile Alexander disease: Spectrum of GFAP mutations and genotype-phenotype correlationAmerican Journal of Human Genetics.  69:1134-1140. 2001
2001 Update on white matter genetic disorders (multiple letters) [2]Pediatric Neurology.  25:347-348. 2001
2000 High susceptibility to cerebral ischemia in GFAP-null miceCerebrovascular and brain metabolism reviews.  20:1040-1044. 2000
2000 Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoterCancer Gene Therapy.  7:1120-1126. 2000
1999 Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgeneLife Sciences.  65:483-491. 1999
1999 Biosynthetic capacity of C6 cells engineered with a glial fibrillary acidic protein-tyrosine hydroxylase transgeneMedical science research.  27:423-425. 1999
1999 Nonlethal detection of transgene expression in the CNS of founder mice 1999
1999 TNF-α pretreatment prevents subsequent activation of cultured brain cells with TNF-α and hypoxia via ceramideAmerican Journal of Physiology.  276. 1999
1998 Suppression of protein synthesis in brain during hibernation involves inhibition of protein initiation and elongation 1998
1998 Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase geneCancer Research.  58:4577-4580. 1998
1998 Astrocytes cultured from transgenic mice carrying the added human glial fibrillary acidic protein gene contain rosenthal fibersJournal of Neuroscience Research.  53:353-360. 1998
1998 Mice lacking GFAP are hypersensitive to traumatic cerebrospinal injuryNeuroReport.  9:1691-1696. 1998
1998 Differentiation-dependent expression of transgenes in engineered astrocyte cell linesNeuroscience Letters.  242:172-176. 1998
1998 Fatal encephalopathy with astrocyte inclusions in GFAP transgenic miceAmerican Journal of Pathology.  152:391-398. 1998
1998 Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental Parkinsonism 1998
1998 Chronic relapsing experimental autoimmune encephalomyelitis: Effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defectsJournal of Neuropathology and Experimental Neurology.  57:426-438. 1998
1998 Stimulation of tyrosine phosphorylation of a brain protein by hibernationCerebrovascular and brain metabolism reviews.  18:1040-1045. 1998
1997 Global forebrain ischemia results in differential cellular expression of interleukin-1β (IL-1β) and its receptor at mRNA and protein levelCerebrovascular and brain metabolism reviews.  17:1107-1120. 1997
1996 Conditional ablation of cerebellar astrocytes in postnatal transgenic mice 1996
1996 Decreased calcium accumulation in isolated nerve endings during hibernation in ground squirrelsNeurochemical Research.  21:947-954. 1996
1996 Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology 1996
1996 GFAP transgenic miceImmunoMethods.  10:351-364. 1996
1996 Somatostatin as a trophic factor: Analysis of transgenic mice overexpressing somatostatin in astrocytesAnnals of the New York Academy of Sciences.  780:29-35. 1996
1995 A novel glial fibrillary acidic protein mRNA lacking exon 1Brain Research.  30:251-258. 1995
1995 Astrocytes Upregulate Glial Fibrillary Acidic Protein (GFAP), but not Insulin‐like Growth Factor‐I (IGF‐I) during Experimental Autoimmune Neuritis (EAN)Brain Pathology.  5:1-10. 1995
1995 Cryogenic spinal cord injury induces astrocytic gene expression of insulin‐like growth factor I and insulin‐like growth factor binding protein 2 during myelin regenerationJournal of Neuroscience Research.  40:647-659. 1995
1995 Overexpression of TGF-ß1 in the central nervous system of transgenic mice results in hydrocephalusJournal of Neuropathology and Experimental Neurology.  54:339-349. 1995
1994 Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitisMolecular and Cellular Neuroscience.  5:418-430. 1994
1994 Concentric sclerosis (Baló): Morphometric and in situ hybridization study of lesions in six patientsAnnals of Neurology.  35:18-30. 1994
1994 Cyclic AMP Decreases the Expression of a Neuronal Marker (GAD67) and Increases the Expression of an Astroglial Marker (GFAP) in C6 CellsJournal of Neurochemistry.  63:1218-1225. 1994
1994 Expression of insulin-like growth factor-I and related peptides during motoneuron regenerationExperimental Neurology.  128:202-210. 1994
1994 GFAP promoter directs astrocyte-specific expression in transgenic mice 1994
1994 Structure and Transcriptional Regulation of the GFAP GeneBrain Pathology.  4:245-257. 1994
1993 Analysis of a Segment of the Human Glial Fibrillary Acidic Protein Gene That Directs Astrocyte‐Specific TranscriptionJournal of Neurochemistry.  61:160-166. 1993
1992 Directed establishment of rat brain cell lines with the phenotypic characteristics of type 1 astrocytes 1992
1991 Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic proteinJournal of Biological Chemistry.  266:18877-18883. 1991
1991 Quantitation of ColE1-encoded replication elements 1991
1990 A downstream initiation element required for efficient TATA box binding and in vitro function of TFIIDNature.  348:86-88. 1990
1990 An RNA polymerase II promoter containing sequences upstream and downstream from the RNA startpoint that direct initiation of transcription from the same site 1990
1990 Characterization of human cDNA and genomic clones for glial fibrillary acidic proteinBrain Research.  7:277-286. 1990
1989 Rom transcript of plasmid ColE1Nucleic Acids Research.  17:4309-4326. 1989
1985 The role of enzyme sequestration in the regulation of the adenylate cyclase of Dictyostelium discoideumJournal of Biological Chemistry.  260:3613-3616. 1985
1984 Transmembrane signaling in Dictyostelium discoideum: A possible mechanism 1984
1983 Forskolin does not activate cyclic AMP synthesis in Dictyostelium discoideum in vivo or in vitroJournal of cyclic nucleotide and protein phosphorylation research.  9:297-303. 1983


Year Title Altmetric
2017 The significance of deiminated GFAP in neurodegenerative diseases with special emphasis on alexander disease.  391-412. 2017
2016 Alexander disease.  23-26. 2016
2014 Alexander disease and astrotherapeutics.  89-105. 2014
2014 Alexander's Disease.  106-109. 2014
2014 Ongoing studies of deimination in neurodegenerative diseases using the F95 antibody.  257-280. 2014
2009 Alexander disease: A genetic disorder of astrocytes.  591-648. 2009
2004 Models of Alexander Disease.  1115-1124. 2004

Education And Training

  • Doctor of Philosophy in Biochemistry, University of California System : Berkeley 1970
  • Full Name

  • Michael Brenner